BRILACIDIN
An immunomodulatory drug candidate with anti-inflammatory and antibiotic properties granted Fast Track status
KEVETRIN
Orphan-designated p53-modulating drug candidate in a Phase 2a trial for late-stage ovarian cancer
Innovation Completes Licensing Agreement with Alfasigma
Alfasigma to Develop Brilacidin for UP/UPS in Inflammatory Bowel Disease
Advancing Brilacidin in the Fight Against COVID-19
Brilacidin being evaluated as a novel Coronavirus therapeutic
An immunomodulatory drug candidate with anti-inflammatory and antibiotic properties granted Fast Track status
Orphan-designated p53-modulating drug candidate in a Phase 2a trial for late-stage ovarian cancer